SuperworthPicard Medical PMI
- Market cap
- $16.6M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.6×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $6.3M
- +41% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- n/m
- not a meaningful number
Picard Medical trades at 2.6× sales. Revenue was $6.3M over the last twelve months, up 41% on a year earlier.
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| $2M | $694K | $881K | $836K | $620K−69% | $2.1M+207% | $1.2M+35% | $1M+21% | $1.1M+86% | $3M+39% | |
| Cost of revenue | $1.2M | $1.1M | $1.6M | $700K | $978K−17% | $2.3M+110% | $1.3M−15% | $598K−15% | $875K−11% | $2.3M+4% |
| Gross profit | $807K | −$382K | −$673K | $136K | −$358K | −$127K−67% | −$130K−81% | $411K+202% | $275K | $616K |
| R&D | $690K | $940K | $961K | $789K | $808K+17% | $743K−21% | $951K−1% | $547K−31% | $1.9M+135% | $1.4M+85% |
| SG&A | $2M | $2.5M | $2.8M | $2.9M | $2.1M+5% | $2.7M+6% | $2.4M−14% | $2.9M−2% | $2.9M+39% | $3.9M+46% |
| −$1.9M | −$3.8M | −$4.4M | −$3.6M | −$3.2M+73% | −$3.5M−8% | −$3.5M−22% | −$3M−16% | −$4.5M+39% | −$4.6M+32% | |
| Interest expense | $82K | $172K | $1.4M | $1.4M | $555K+577% | $2.4M+1311% | $2.4M+74% | $7K−100% | $5K−99% | $89K−96% |
| Pre-tax income | −$2M | −$4.1M | −$6.2M | −$8.9M | −$5.5M+183% | −$6.7M+66% | −$10.4M+68% | −$4.3M−52% | −$7.6M+38% | −$5.7M−16% |
| n/a | n/a | $0 | −$15K | $31K | $0 | $0 | $4K | $0 | $7K | |
| Net income | −$2M | −$4.1M | −$6.2M | −$8.8M | −$5.6M+185% | −$6.7M+66% | −$10.4M+68% | −$4.3M−51% | −$7.6M+37% | −$5.7M−16% |
| −$16.50 | −$29.50 | n/a | n/a | −$40.00+142% | −$42.39+44% | n/a | n/a | n/a | n/a | |
| 158.9K | 158.9K | n/a | n/a | 158.8K−0% | 176.5K+11% | n/a | n/a | n/a | n/a |
Revenue: Q1 FY24: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY24: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
R&D: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
SG&A: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Operating income: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Net income: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
EPS, diluted: 4 periods, Q1 FY24 to Q2 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY24 and Q1 FY25: share-days: the 6-month average less the second quarter's.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Picard Medical's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| PMIPicard Medical | $16.6M | n/m | n/a | 2.6× | +41% | n/m | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| Peer median | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% |
More on Picard Medical
Each number over time
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .